The bacteria are like a sensitive alarm system for early cancer
En los laboratorios de la Universidad de Chicago, investigadores han encontrado una forma de escuchar lo que las bacterias del intestino tienen que decir sobre el cáncer que aún no se ve: un análisis de sangre que lee modificaciones en el ARN microbiano detecta el cáncer colorrectal en sus etapas más tempranas con un 95% de precisión. Este hallazgo, publicado en Nature Biotechnology, no solo supera con creces los métodos actuales —que fallan en más de la mitad de los casos tempranos— sino que redefine dónde buscar las señales de la enfermedad. La vida invisible que habita en nosotros resulta ser, quizás, nuestro centinela más fiel.
- El cáncer colorrectal mata en silencio: los métodos actuales de detección temprana fallan en más del 50% de los casos cuando la enfermedad aún es tratable.
- Las biopsias líquidas tradicionales buscan ADN tumoral en sangre, pero en etapas iniciales las células cancerosas liberan tan poco material genético que la señal se pierde entre el ruido.
- El equipo del bioquímico Chuan He apostó por un camino radicalmente distinto: medir las modificaciones químicas del ARN que liberan las bacterias intestinales, cuya actividad se altera cuando un tumor comienza a crecer y genera inflamación.
- El resultado es un test con 95% de precisión global que mantiene su fiabilidad incluso en los estadios más tempranos, algo que He describe como sin precedentes en el campo.
- El camino hacia la clínica aún requiere ensayos en poblaciones más amplias y diversas, pero si los resultados se confirman, este análisis de sangre podría convertirse en una herramienta de cribado masivo que salve miles de vidas.
Investigadores de la Universidad de Chicago han desarrollado un análisis de sangre capaz de detectar el cáncer colorrectal en sus etapas más tempranas con un 95% de precisión, según un estudio publicado esta semana en Nature Biotechnology. El avance representa un giro conceptual respecto a las biopsias líquidas convencionales y abre una nueva vía en el diagnóstico oncológico.
Las pruebas actuales buscan fragmentos de ADN tumoral circulante en sangre, un enfoque que funciona cuando el tumor ya es grande, pero que fracasa en fases iniciales: los tests comerciales más avanzados caen por debajo del 50% de precisión cuando el cáncer aún es pequeño y libera cantidades mínimas de material genético. Esta brecha diagnóstica ha sido una fuente persistente de frustración clínica.
El equipo liderado por el profesor Chuan He optó por mirar en otro lugar: el microbioma intestinal. Cuando un tumor comienza a crecer en el colon, la inflamación que genera obliga a las bacterias circundantes a reorganizarse. Esos microbios mueren y se renuevan a un ritmo mucho mayor que las células humanas, liberando constantemente fragmentos de ARN al torrente sanguíneo. Al medir las modificaciones químicas específicas de ese ARN bacteriano —etiquetas que reflejan el nivel de actividad microbiana— los investigadores identificaron patrones inequívocamente asociados a tumores tempranos.
Es la primera vez que las modificaciones del ARN se emplean como biomarcador oncológico, y los resultados mostraron diferencias sustanciales entre pacientes con cáncer y controles sanos. He subraya que la sensibilidad del método supera la de medir simplemente la abundancia de ARN. El siguiente paso son ensayos clínicos en poblaciones más amplias; si confirman la eficacia del test, podría transformar el cribado del cáncer colorrectal y aumentar significativamente las posibilidades de curación al detectar la enfermedad cuando el tratamiento es más efectivo.
American researchers have developed a blood test that detects colorectal cancer in its earliest stages with 95% accuracy—a significant leap forward from the screening methods currently available in clinical practice.
The test, developed by scientists at the University of Chicago and published this week in Nature Biotechnology, works by measuring changes in RNA rather than DNA. It represents a fundamental shift in how doctors might catch this disease before it becomes difficult to treat. The breakthrough hinges on an unexpected source: the trillions of bacteria living in the human gut.
Traditional liquid biopsies have long promised a simpler alternative to invasive tissue sampling. A doctor draws blood, and the test hunts for fragments of DNA shed by dying cancer cells circulating in the bloodstream. The approach works reasonably well once a tumor has grown large enough to release substantial amounts of genetic material. But in the earliest stages, when cancer cells are still multiplying and haven't yet begun dying in significant numbers, there simply isn't enough tumor DNA in the blood to reliably detect. This detection gap has been a persistent frustration in cancer screening. Commercial tests measuring DNA or RNA in stool samples achieve roughly 90% accuracy for advanced cancers but drop below 50% accuracy for early-stage disease.
Chuan He, a biochemistry professor leading the research, and his team approached the problem differently. Instead of looking for human tumor DNA, they measured circulating RNA—genetic material released not just by cancer cells, but by the microbiota, the bacterial ecosystem that inhabits the digestive tract. When a tumor begins growing in the colon, it triggers inflammation. That inflammation forces the surrounding microbiome to reorganize and adapt. The bacteria respond by changing their activity patterns, which leaves a detectable signature in the RNA they release into the bloodstream.
The key insight was that bacterial populations turn over far more rapidly than human cells. Billions of microbes die and release their genetic fragments into the blood every day, creating a constant stream of information about the gut environment. By measuring specific modifications in this microbial RNA—chemical tags that reflect how active the bacteria are—the researchers could identify patterns associated with early-stage tumors. The test achieved 95% overall accuracy and remained precise even in the earliest cancer stages, a result He describes as unprecedented.
The researchers tested their approach on blood samples from colorectal cancer patients and healthy controls. They found substantial differences in the RNA modifications released by gut bacteria in cancer patients compared to healthy people. The modifications reflected the biological stress the microbiome experiences when a tumor is present and growing. This indirect measurement—reading the cancer signal through the lens of bacterial response—proved far more sensitive than trying to detect the sparse DNA fragments released by early-stage human tumor cells.
He emphasizes that this is the first time RNA modifications have been used as a potential cancer biomarker, and the results suggest the approach is both more reliable and more sensitive than measuring RNA abundance alone. The next steps will involve larger clinical trials to confirm the test's effectiveness in diverse populations and to understand whether it can be translated into a practical screening tool for widespread use. If those trials succeed, this blood test could fundamentally change how doctors approach colorectal cancer detection, catching the disease when treatment is most likely to succeed.
Citações Notáveis
In early cancer stages, there simply isn't enough tumor DNA in the blood to reliably detect—a persistent frustration in cancer screening.— Research findings
This is the first time RNA modifications have been used as a potential cancer biomarker, and the results suggest the approach is both more reliable and more sensitive than measuring RNA abundance alone.— Chuan He, University of Chicago
A Conversa do Hearth Outra perspectiva sobre a história
Why does the microbiome matter here? Couldn't you just look harder for tumor DNA?
In early cancer, there's barely any tumor DNA in the blood yet. The tumor is small, cells aren't dying fast enough to release much. But the microbiome is constantly turning over—billions of bacteria dying every day. When inflammation from the tumor hits, those bacteria change how they work, and that shows up in their RNA.
So you're reading the cancer indirectly, through the bacteria's reaction to it?
Exactly. The bacteria are like a sensitive alarm system. They respond to the tumor's presence before the tumor has shed enough of its own DNA to be detectable. It's a much earlier warning signal.
The accuracy jumps from below 50% to 95%. That's enormous. What's the catch?
Right now it's been tested on blood samples in the lab. The real question is whether it works in a real screening program with thousands of people. And whether the test can be made simple and affordable enough for doctors to actually use it.
How soon could someone get this test?
That depends on clinical trials. The science is solid, but moving from research to something a patient can walk into a clinic and get takes time. Years, probably.
If it works, what changes?
Colorectal cancer caught at stage one has a much higher survival rate than stage three or four. A test this accurate in early stages could save a lot of lives.